TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026

Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics

“The breadth and consistency of the data presented at MSToronto2026 further reinforce our confidence in BRIUMVI as a leading treatment option for relapsing MS. The seven-year results are particularly compelling, with approximately 88% of continuously treated patients remaining free of confirmed disability progression, supported by an increasingly robust body of real-world evidence demonstrating strong disease control, favorable tolerability, and high patient satisfaction. We are also encouraged by emerging evidence from patients transitioning from other anti-CD20 therapies, which continues to inform our understanding of BRIUMVI’s differentiated clinical profile.”

Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics

“Equally exciting is the progress we are making toward the next generation of BRIUMVI. Our positive Phase 3 ENHANCE results support the potential to simplify IV treatment initiation to a single infusion, while our Phase 1 subcutaneous results provide strong support for the quarterly dosing regimen being evaluated in our fully enrolled Phase 3 trial. Together, these advances have the potential to strengthen our IV franchise while opening an entirely new segment of the anti-CD20 market, positioning BRIUMVI to become an increasingly important treatment option for patients with relapsing MS, regardless of their preferred route of administration.”